TWEAK/Fn14 system and crescent formation in IgA nephropathy

BMC Nephrology

Yasuhiko Tomino¹  Satoshi Horikoshi¹  Yusuke Suzuki¹  Yoshio Shimizu¹  Yohei Sasaki¹ 

[1] Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, 2-1-1, Hongo, Tokyo 113-8421, Bunkyo-ku, Japan

关键词: Proteinuria;    Crescent formation;    IgA nephropathy;    TWEAK;   

Others  :  1143828
DOI  :  10.1186/s12882-015-0022-8

 received in 2014-11-14, accepted in 2015-02-20,  发布年份 2015

【 摘 要 】

Background

The TNF-like weak inducer of apoptosis (TWEAK) contributes to kidney inflammation producing secretion by renal cells. The present study examined whether the level of TWEAK is associated with histologic findings in patients with IgA nephropathy (IgAN).

Methods

The levels of urinary TWEAK (uTWEAK) from 116 IgAN patients, 50 non-IgA kidney disease patients, and 50 healthy individuals were measured by ELISA. Histological findings of renal biopsy specimens of patients with IgAN were evaluated according to the Oxford classification and histological classification for IgAN in Japan. We investigated the expression of TWEAK/Fn14 in renal tissues of those patients and assessed the effect of TWEAK in glomerular mesangial cells and podocytes.

Results

The levels of uTWEAK in the patients with IgAN and other renal diseases were significantly higher than in the healthy controls (P < 0.001). In the IgAN patients, the levels of uTWEAK correlated significantly with urinary protein excretion and extracapillary proliferation (r = 0.54, P < 0.001 and r = 0.32, P < 0.001, respectively). In a comparison of the levels of uTWEAK at diagnosis with that of follow-up, the levels of uTWEAK in patients with clinical and partial remission decreased significantly. We showed not only increased expression of both TWEAK and Fn14 in IgAN patients with glomerular crescents but also TWEAK-induced cell motility in podocytes.

Conclusions

The relationship between the levels of uTWEAK and clinicopathological findings observed in this study suggests that TWEAK/Fn14 system affects crescent formation and proteinuria in patients with IgAN.

【 授权许可】

   
2015 Sasaki et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al.: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272:32401-10.
• [2]Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-25.
• [3]Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al.: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001, 15:837-46.
• [4]Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al.: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000, 156:1253-61.
• [5]Sanz AB, Sanchez-Niño MD, Ortiz A: TWEAK, a multifunctional cytokine in kidney injury. Kidney Int 2011, 80:708-18.
• [6]Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, et al.: Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1716-23.
• [7]Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, Heimburger O, et al.: Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:110-8.
• [8]Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, et al.: Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006, 27:242-50.
• [9]Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, et al.: Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009, 11:R143. BioMed Central Full Text
• [10]D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987, 64:709-27.
• [11]Nair R, Walker PD: Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006, 69:1455-8.
• [12]Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med 2013, 368:2402-14.
• [13]Greka A, Mundel P: Cell biology and pathology of podocytes. Annu Rev Physiol 2012, 74:299-323.
• [14]Asao R, Asanuma K, Kodama F, Akiba-Takagi M, Nagai-Hosoe Y, Seki T, et al.: Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol 2012, 7:1385-93.
• [15]Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, et al.: Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002, 61:1475-85.
• [16]Tomino Y: Pathogenesis of IgA nephropathy. Contrib Nephrol 2007, 157:1-7.
• [17]Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, et al.: Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006, 70:1750-8.
• [18]Gao HX, Campbell SR, Burkly LC, Jakubowski A, Jarchum I, Banas B, et al.: TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 1997, 46:24-35.
• [19]Sanz AB, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, Kreztler M, et al.: The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008, 19:695-703.
• [20]Izquierdo MC, Sanz AB, Mezzano S, Blanco J, Carrasco S, Sanchez-Nino MD, et al.: TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 2012, 81:1098-107.
• [21]Moreno JA, Izquierdo MC, Sanchez-Nino MD, Suarez-Alvarez B, Lopez-Larrea C, Jakubowski A, et al.: The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol 2011, 22:1315-25.
• [22]Sanz AB, Izquierdo MC, Sanchez-Nino MD, Ucero AC, Egido J, Ruiz-Ortega M, et al.: TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant 2014, 29:i54-62.
• [23]Campbell S, Burkly LC, Gao HX, Berman JW, Su L, Browning B, et al.: Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006, 176:1889-98.
• [24]Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al.: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009, 76:534-45.
• [25]Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al.: The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009, 76:546-56.
• [26]Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, et al.: Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 2014, 18:481-6.
• [27]Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al.: Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-92.
• [28]Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Miyazaki Y, et al.: A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol 2013, 26:350-7.
• [29]Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: past, present, and future. Kidney Int 2007, 72:26-36.
• [30]Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, Mundel P: Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 2006, 8:485-91.
• [31]Hidaka T, Suzuki Y, Yamashita M, Shibata T, Tanaka Y, Horikoshi S, et al.: Amelioration of crescentic glomerulonephritis by RhoA kinase inhibitor, Fasudil, through podocyte protection and prevention of leukocyte migration. Am J Pathol 2008, 172:603-14.
• [32]Ruiz-Ortega M, Ortiz A, Ramos AM, Ramos AM: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. Curr Opin Nephrol Hypertens 2014, 23:93-100.
• [33]Sanchez-Nino MD, Poveda J, Sanz AB, Mezzano S, Carrasco S, Fernandez-Fernandez B, et al.: Fn14 in podocytes and proteinuric kidney disease. Biochim Biophys Acta 1832, 2013:2232-43.
• [34]Burt D, Salvidio G, Tarabra E, Barutta F, Pinach S, Dentelli P, et al.: The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am J Pathol 2007, 171:1789-99.
• [35]Lee EY, Chung CH, Khoury CC, Yeo TK, Pyagay PE, Wang A, et al.: The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol 2009, 297:F85-94.
• [36]Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, et al.: Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009, 58:2109-18.
• [37]Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al.: Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014, 86:828-36.
• [38]Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al.: Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011, 80:310-7.
• [39]Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ, Chen YQ, et al.: Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol 2011, 6:2175-84.
• [40]EdströmHalling S, Söderberg MP, Berg UB: Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 2012, 27:715-22.
• [41]Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H: Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol 2011, 12:2806-13.
• [42]Bariety J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacquot C: Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int 2005, 68:1109-19.
• [43]Thorner PS, Ho M, Eremina V, Sado Y, Quaggin S: Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 2008, 19:495-502.
• [44]Sistani L, Rodriguez PQ, Hultenby K, Uhlen M, Betsholtz C, Jalanko H: Neuronal proteins are novel components of podocyte major processes and their expression in glomerular crescents supports their role in crescent formation. Kidney Int 2013, 83:63-71.
• [45]Kriz W, LeHir M: Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005, 67:404-19.
• [46]Tipping PG, Holdsworth SR: T cells in crescentic glomerulonephritis. J Am Soc Nephrol 2006, 17:1253-63.